3 ms·

Huh. I've been told that ibogaine "short-circuits" the withdrawl process, and so googled ibogaine + norepinephrine and got this paper: https://www.ncbi.nlm.nih

Huh. I've been told that ibogaine "short-circuits" the withdrawl process, and so googled ibogaine + norepinephrine and got this paper: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3365767/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3365767/ In contrast [with Ibogaine], all other known SERT inhibitors are competitive with substrate (28). These competitive inhibitors include several compounds that also inhibit the closely related dopamine and norepinephrine transporters Does someone with enough knowledge to actually understand this paper want to chime in and maybe explain? It seems well-written, but reliant upon knowing, what, say, SERT and DAT are. Edit: This other paper also came up: https://www.ncbi.nlm.nih.gov/pubmed/7568622 https://www.ncbi.nlm.nih.gov/pubmed/7568622

LnxPrgr3 10y ago
I am not an expert, but since no one has answered I'll give what I know and hope somebody corrects me if I'm terribly wrong. Substrate: the thing that's supposed to bind to something normally. SERT: transporter that pulls serotonin out of synapses back into the neuron that put them there in the first place. DAT: similar, but for dopamine and to some degree norepinephrine. Competitive inhibition: inhibition depends on whether the intended substrate for a site is present—the drug and substrate interfere with each other competitively. Non-competitive inhibition: the drug inhibits the function of a site even if the intended substrate is already bound to it. As to how any of this explains or refutes claims ibogaine short-circuits withdrawal, I dunno. Feels a bit like trying to explain JavaScript in terms of quantum mechanics. Both these papers are evaluating the drug's interaction with neurons, not the drug's effect or non-effect on addiction.